Behavioral health company LifeStance Health (NASDAQ: LFST) will be reporting earnings this Thursday before the bell. Here’s what to expect.
LifeStance Health Group met analysts’ revenue expectations last quarter, reporting revenues of $333 million, up 10.8% year on year. It was a mixed quarter for the company, with a solid beat of analysts’ EPS estimates but EBITDA guidance for next quarter missing analysts’ expectations significantly.
Is LifeStance Health Group a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting LifeStance Health Group’s revenue to grow 10.8% year on year to $346.2 million, slowing from the 20.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.03 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. LifeStance Health Group has missed Wall Street’s revenue estimates twice over the last two years.
Looking at LifeStance Health Group’s peers in the outpatient & specialty care segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Encompass Health delivered year-on-year revenue growth of 12%, beating analysts’ expectations by 2.2%, and Surgery Partners reported revenues up 8.4%, topping estimates by 1.2%. Encompass Health traded up 4.2% following the results.
Read our full analysis of Encompass Health’s results here and Surgery Partners’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the outpatient & specialty care stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. LifeStance Health Group is down 16.1% during the same time and is heading into earnings with an average analyst price target of $8.44 (compared to the current share price of $3.92).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
